Logo-npj
Submitted: 10 Jul 2023
Accepted: 01 Nov 2023
ePublished: 27 Nov 2023
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

J Nephropharmacol. 2024;13(1): e11651.
doi: 10.34172/npj.2023.11651
  Abstract View: 585
  PDF Download: 273

Meta Analysis

The association between metformin administration and non-Hodgkin lymphoma; a systematic review and meta-analysis of cohort and case-control studies

Elnaz Ataei 1 ORCID logo, Razieh Bagheri Shahzadeh Aliakbari 2 ORCID logo, Navid Asgari 3 ORCID logo, Nasim Zaman Samghabadi 4 ORCID logo, Sina Salati 5 ORCID logo, Sara Abbasian 6 ORCID logo, Mohammad Akbari 7 ORCID logo, Farshad Gharebakhshi 8,9 ORCID logo, Anna Ghorbani Doshantapeh 10* ORCID logo

1 Clinical Research Development Center, Shahid Modarres Educational Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 Biomedical Engineering and Rehabilitation Sciences, Louisiana Tech University, Ruston, Louisiana, USA
3 Department of Internal Medicine, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
4 Department of Infectious Diseases, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
5 Department of Nursing, Kashmar School of Medical Sciences, Mashhad University of Medical Sciences, Mashhad, Iran
6 Department of Nursing, Faculty of Nursing and Midwifery, Tehran University of Medical Sciences, Tehran, Iran
7 Department of Nursing, Faculty of Nursing and Midwifery, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
8 Department of Radiology, Imam Hossein Hospital, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
9 Guissu Research Corporation, Bandar Abbas, Iran
10 Department of Hematology-Medical Oncology, Shahid Beheshti University of Medical Sciences, Tehran, Iran
*Corresponding Author: Anna Ghorbani Doshantapeh, Email: annaghorbani1367@gmail.com

Abstract

Introduction: Metformin, a blood sugar-lowering agent, has the potential to be an anti-cancer agent. However, its role in lymphoma remains uncertain.

Objectives: This study sought to examine the correlation between the utilization of metformin and non-Hodgkin lymphoma through the application of a systematic review and meta-analysis methodology.

Materials and Methods: This investigation was carried out in the form of a methodical examination and meta-analysis in accordance with the PRISMA guidelines. Databases such as Scopus, PubMed, Web of Science, Cochrane, and the Google Scholar search engine were thoroughly explored without any temporal limitations until September 20, 2023. The data was analyzed utilizing the STATA 14 software, and the level of significance for the tests was established at P<0.05.

Results: The results, obtained by combining six observational studies (five cohort studies and one case-control study) with a total sample size of 2 330 787 individuals, showed that the odds ratio (OR) for the association between metformin use and non-Hodgkin lymphoma in all studies was 0.91 (95% CI: 0.78, 1.07). In cohort studies, the OR was 0.91 (95% CI: 0.74, 1.11), and in the case-control study, it was 0.93 (95% CI: 0.79, 1.10). None of these relationships were statistically significant. The odds ratio between metformin uses and chronic lymphocytic leukemia/small lymphocytic leukemia was 0.93 (95% CI: 0.71, 1.21), and the odds ratio between metformin use and diffuse large B-cell lymphoma was 1.06 (95% CI: 0.61, 1.83), both of which were not statistically significant.

Conclusion: This investigation’s findings indicated no statistically noteworthy correlation exists between the utilization of metformin and the probability of contracting non-Hodgkin lymphoma, chronic lymphocytic leukemia/small lymphocytic leukemia, and diffuse large B-cell lymphoma.

Registration: This study was conducted following the PRISMA checklist. Its protocol was registered on the PROSPERO (CRD42023469100) and Research Registry (UIN: reviewregistry1721) websites.


Implication for health policy/practice/research/medical education:

The results, obtained by combining six observational studies (five cohort studies and one case-control study) with a total sample size of 2 330 787 individuals, showed that metformin has no significant effect on the occurrence of non-Hodgkin lymphoma, chronic lymphocytic leukemia/small lymphocytic leukemia, and diffuse large B-cell lymphoma. However, considering the aforementioned limitations and the limited number of studies, it appears that more research studies are needed.

Please cite this paper as: Ataei E, Bagheri Shahzadeh Aliakbari R, Asgari N, Zaman Samghabadi N, Salati S, Abbasian S, Akbari M, Gharebakhshi F, Ghorbani Doshantapeh A. The association between metformin administration and non-Hodgkin lymphoma; a systematic review and meta-analysis of cohort and case-control studies. J Nephropharmacol. 2024;13(1):e11651. DOI: 10.34172/npj.2023.11651.

First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 586

Your browser does not support the canvas element.


PDF Download: 273

Your browser does not support the canvas element.